Improved blood analysis panel for the early detection of thromboses and thrombotic risk factors

Introduction The incidence of deep vein thrombosis (DVT) in the general population is estimated at one to two cases per 1,000 people per year, making it one of the most common diseases in Germany. More than 900,000 patients suffer from the consequences of DVT, although the number of unreported cases is much higher. In addition to complications such as post-thrombotic syndrome and pulmonary embolism, DVT is associated with a high mortality rate. Every year, more than 40,000 people in Germany die from thrombosis. A comprehensive and thorough analysis of the factors that lead to an increased risk of thrombosis is therefore urgently required. Method In our practice, around 4800 patients with statutory health insurance are examined annually for possible blood clotting disorders. In this study, we have carried out a retrospective analysis of the risk factors for thrombosis in the blood of 1200 patients, who came to us from october to december 2024. Of the 1,200 total patients, 938 had a suspected thrombophilia, 112 were pregnant patients (many with a previous history of abortion), 119 patients with a suspected bleeding tendency. In addition to the parameters for blood tests for thrombosis risks promoted by the statutory health insurance companies, we have increased the range of tests in our practice in order to minimise the number of undetected patients at risk. Genetic mutation analysis of factor V Leiden and factor II 20210 was supplemented by factor II 19911, fibrinogen alpha, beta, gamma, PAI-1, FSAP, Factor XIII 102, and factor V HR2. Furthermore, the concentration of protein Z was analysed in addition to the usually tested parameters. Results Almost all of our patients had at least one thrombosis-related mutation. If only genetic factors are examined, the new panel identifies approximately twice as many patients with an increased risk (38% new panel vs. 18% old panel). If protein Z concentration and other known thrombosis risk factors are also taken into account, the detection rate increases by a further 30% to a total rate of 68%. With the new panel we could show that 46% of patients classified as low risk by the statutory health insurance have a relevant risk of thrombosis. Conclusion In this study, we were able to show that an extended panel of blood parameters, both at the congenital and acquired level, was able to identify patients at risk of thrombosis far better than the specifications of the statutory health insurance scheme. By recognising a potential risk at an early stage, it is possible to react faster and better and thus improve patient well-being and even reduce the financial burden on health insurance companies by preventing thromboses. Publication History Article published online: 17 February 2026 © 2026. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany